Predicting TCR Specificity with Multiomic Single-Cell Sequencing

You will be hearing from a variety of Scientists from Wyatt Technology who will help explain some of the key advancements and improvements made in light scattering that we believe will provide future customers with state-of-the-art capabilities and unique benefits.

De-Risky Business: Assessing Biotherapeutic Off-Target and On-Target Liabilities Toxicity failures caused by off-target or unintended on-target liabilities are a leading cause of attrition in clinical and preclinical programs. Given the effort, cost, and technical limitations of traditional biopharmaceutical de-risking strategies, there is a need for a robust and scalable approach that can be rapidly applied to the discovery phases of therapeutic programs. Join us for this exciting new GEN Webinar, where our panel of experts will discuss new approaches to de-risking lead selection of antibodies and other biotherapeutics.

The Biotechnology Risk Assessment Research Grants (BRAG) program supports the generation of new information that will assist federal regulatory agencies in making science-based decisions about the environmental effects of introducing genetically engineered organisms.

We will introduce Chromassette® and an application example of an integrated rapid single pass process from harvest to purified bulk, a concept demonstrated by AbbVie. Chromassette is a stackable, single-use and pre-packed chromatography cassette with a supported bed, addressing the current key challenges in manufacturing. Chromassette enhances the separation capabilities of chromatography resins and combines it with the convenience of a modular cassette.